This approach capitalizes on the specificity of YSA-LP for EphA2-expressing cells to facilitate targeted delivery of DOX, thereby improving the therapeutic impact on cancer cells through increased precision and potency [94]. This evidence concerns the gene EPHA2 and cancer.